Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473732 · ClinicalTrials.gov registry record · NA
Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
A NA study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01473732 is a NA study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT01473732, a NA study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how well the current drug regimen (including low Prograf dose and Myfortic, which is usually recommended to prevent any further deterioration in the kidney function) works and how safe it is when compared to a combination of Zortress and Myfortic in patients with chronic kidney injury associated with Prograf or Neoral use.
Interventions
- DRUG Everolimus
- DRUG Tacrolimus
- DRUG Mycophenolic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473732
The ClinicalTrials.gov registry entry for NCT01473732 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Everolimus is the first listed.
NCT01473732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473732 about?
NCT01473732 is a clinical study titled "Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity". The purpose of this study is to find out how well the current drug regimen (including low Prograf dose and Myfortic, which is usually recommended to prevent any further deterioration in the kidney function) works and how safe it is when compared to a combination of Zortress and Myfortic in patients ...
What is the current status of trial NCT01473732?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2012-03. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01473732?
The interventions under investigation include: Everolimus (DRUG), Tacrolimus (DRUG), Mycophenolic acid (DRUG).
Who is sponsoring clinical trial NCT01473732?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.